静脉用蔗糖铁治疗血液透析患者肾性贫血的疗效观察及护理

目的探讨静脉补铁对肾性贫血的疗效及护理。方法 46例维持血液透析的贫血患者分为静脉和口服两组,治疗8周后观察其Hb、RBC等各项指标的变化。结果静脉组治疗前后的Hb为(70.05±16.19)g/L及(86.19±13.04)g/L,RBC为(2.51±0.56)×1012/L及(3.08±0.65)×1012/L,Hct为0.218±0.051及0.274±0.046,SF为(215.43±98.31)μg/L及(510.99±136.96)μg/L,TSAT为(21.03±5.83)%及(33.51±7.47)%,差异具有统计学意义(P均<0.01);且Hb、Hct、SF、TSAT增高幅度明显高于口服组(P<0.05)。口服组治疗前后各指标均无统计学差异。结论静脉补铁治疗血液透析患者肾性贫血疗效优于口服铁剂。

Observation of Effect of Intravenous Iron Sucrose in Hemodialysis in Treatment of Patients with Renal Anemia and Its Nursing

Objective To explore the effect and nursing of intravenous iron therapy in renal anemia.Methods 46 anaemic patients with maintenance hemodialysis were divided into intravenous group and oral group.The indicators of Hb、RBC、etc were observed after treatment for 8 weeks.Result The Hb was（70.05±16.19） g/L and（86.19±13.04）g/L,and the RBC was（2.51±0.56）×1012/L and（3.08±0.65）×1012/L,and the Hct was 0.218±0.051 and 0.274±0.046,the SF was（215.43±98.31） μg/L and（510.99±136.96）μg/L,the TSAT was（21.03±5.83）% and（33.51±7.47）%.The difference had a statistical significance（P0.01）.The increases extent of Hb、Hct、SF、TSAT was obvious higher in ntravenous group than in oral group.There was no statistical difference in oral group before and after treatment.Conclusion The effect of intravenous iron therapy is better than oral iron therapy in treatment of renal anemia by hemodialysis.